Dr Kilian Kelly has over 20 years’ experience in biopharmaceutical research and development, including almost 15 years focussed on the development of mesenchymal stem cell (MSC) based therapies. He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer from May 2019, and since July 2023 has been CEO & MD. At Cynata, he has overseen all stages of the development of the Cymerus™ induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide.

Dr Kelly previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca. He holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow, and he is a Graduate of the Australian Institute of Company Directors (AICD), Melbourne. He is a member of the International Society for Cell and Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), the Royal Pharmaceutical Society and the AICD. Dr Kelly also serves on the ISCT Asia-Pacific Industry Committee, the ISSCR Best Practices Working Group for the Development of PSC-Derived Therapies and the Industry Interface Committee of the Center for Commercialisation of Regenerative Medicine (CCRM) Australia.

Dr Mathias Kroll has over 25 years’ experience in biopharmaceutical research and business development. He joined the Company in April 2024 as Chief Business Officer. Dr. Kroll has extensive global experience in biopharmaceutical business transactions of all kinds and has created and managed a large number of partnerships ranging in value up to several billion dollars.

His previous appointments are Chief Commercial Officer, QIMR Berghofer (AUS), Chief Executive Officer, InProTher ApS (DK, now Hervolution Therapeutics), Global Head of Business Development, Bavarian Nordic (DK), Sr Director Global Business Development, GlaxoSmithKline Vaccines (BE), Assoc. Product Director and Global Brand Manager, UCB (BE), Assoc. Director Business Development, UCB Japan (JP), Research Unit Head, Sanofi (FR), Laboratory Head, Bayer Healthcare (DE), Vis. Assoc. Consultant, Boston Consulting Group (DE), and Research Associate, INSERM (FR). Following studies and research work performed at the Universities of Dusseldorf (DE), Paris (FR), North Carolina at Chapel Hill (USA), and at IMD in Lausanne (CH), Dr Kroll holds Master’s degrees in Chemistry, Biology, and Business Administration, a diploma in Molecular Virology, and a PhD in Viral Immunology for work performed at Pasteur Institute (FR). He is a member of the Australian Institute of Company Directors. He also serves on the Selection Panel of CUREator, Australia’s national biotech incubator.

Dr Airey is an accomplished biopharmaceutical executive and physician with broad international experience in the successful development and commercialisation of pharmaceutical products including novel biological agents. She has been involved in the design and execution of multiple clinical trials from early through to late stage, encompassing a wide range of therapeutic categories in multiple geographies. Dr Airey joined Cynata in October 2021 from CSL Limited, where she was Director, Translational Development. Prior to CSL, Dr Airey was a Clinical Development Physician at Seqirus, a CSL company, and earlier held a range of medical positions within biotech, pharmaceutical and clinical research companies. Her career path has led to her playing important roles in the market approvals of several drug products.